| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Association of cancer with comorbid inflammatory conditions and treatment in patients with Lynch syndrome
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Muhammad S Faisal, Carol A Burke, David Liska, Amy L Lightner, Brandie Leach, Margaret O’Malley, Lisa LaGuardia, Benjamin Click, JP Achkar, Matthew Kalady, JM Church and Gautam Mankaney |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Gautam Mankaney, MD, Doctor, Doctor, Department of Gastroenterology and Hepatology, Virginia Mason Franciscan Health, Department of Gastroenterology and Hepatology, Virginia Mason, 1100 Ninth Avenue C3-GAS, Seattle WA, 98101
Electronic address: mankaneg@gmail.com, Seattle, 98101, United States. mankaneg@gmail.com |
| Key Words |
Lynch syndrome; Hereditary non-polyposis colorectal cancer; Inflammatory bowel disease; Immunosuppression; Biologics |
| Core Tip |
Individuals with hereditary non-polyposis colorectal cancer (HNPCC) are at increased risk of both colorectal cancer and other cancers. When they have a comorbid inflammatory condition (CID) that requires immunosuppression, clinicians may be hesitant to prescribe these medications due to concern of an elevated cancer risk. We show that individuals with HNPCC and CID have a similar cancer risk to those with HNPCC alone, and that the addition of immunosuppression does not increase overall cancer risk, but may increase the risk of LS-specific cancers. |
| Publish Date |
2022-01-22 06:17 |
| Citation |
Faisal MS, Burke CA, Liska D, Lightner AL, Leach B, O’Malley M, LaGuardia L, Click B, Achkar J, Kalady M, Church J, Mankaney G. Association of cancer with comorbid inflammatory conditions and treatment in patients with Lynch syndrome. World J Clin Oncol 2022; 13(1): 49-61 |
| URL |
https://www.wjgnet.com/2218-4333/full/v13/i1/49.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v13.i1.49 |
